Press Releases

Date	Title	PDF Version
Nov 19, 2015	Alexion to Highlight Robust Rare Disease Pipeline at Investor Day
Nov 07, 2015	Long-Term Follow-up Study Presented at ASN 2015 Supports Effectiveness of Soliris® (eculizumab) in Preventing Thrombotic Microangiopathy (TMA) Events in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Nov 05, 2015	Researchers to Present Data on Enhancing the Understanding of PNH and aHUS and Underscoring the Effectiveness of Soliris® (eculizumab) Treatment at ASH 2015 Annual Meeting
Oct 29, 2015	Alexion Reports Third Quarter 2015 Results
Oct 23, 2015	FDA Approves Strensiq™ (asfotase alfa) for Treatment of Patients with Perinatal-, Infantile- and Juvenile-Onset Hypophosphatasia (HPP)
Oct 12, 2015	Significant Improvements in Skeletal Mineralization and Physical Function Observed in Children with Hypophosphatasia (HPP) Treated With Strensiq™ (asfotase alfa) Sustained for at least Five Years
Oct 12, 2015	Alexion Pharmaceuticals to Report Third Quarter 2015 Results on Thursday, October 29, 2015
Oct 02, 2015	Alexion Announces Presentations at ASN 2015, Including a Long-Term Follow-Up Study of Soliris® (eculizumab) for the Prevention of Thrombotic Microangiopathy (TMA) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Sep 16, 2015	Alexion Announces Presentations at 2015 American Society for Bone and Mineral Research Annual Meeting, Including New Data on Strensiq™ (asfotase alfa) in Children with Hypophosphatasia (HPP) Treated for Five Years
Sep 09, 2015	New England Journal of Medicine (NEJM) Publishes Pivotal Phase 3 Data on Kanuma™ (sebelipase alfa) in Children and Adults with Lysosomal Acid Lipase Deficiency (LAL-D)

Press Releases

Press Releases

Search